The thrombospondins.
Adams, Josephine C, and Jack Lawler. 2011. “The Thrombospondins.”. Cold Spring Harbor Perspectives in Biology 3 (10): a009712.
Search
Search results
215 results found
Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.
Nucera, Carmelo, Matthew A Nehs, Sushruta S Nagarkatti, Peter M Sadow, Michal Mekel, Andrew H Fischer, Paul S Lin, et al. 2011. “Targeting BRAFV600E With PLX4720 Displays Potent Antimigratory and Anti-Invasive Activity in Preclinical Models of Human Thyroid Cancer.”. The Oncologist 16 (3): 296-309.
The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?
Nucera, Carmelo, Jack Lawler, Richard Hodin, and Sareh Parangi. 2010. “The BRAFV600E Mutation: What Is It Really Orchestrating in Thyroid Cancer?”. Oncotarget 1 (8): 751-6.
Tumor progression: the effects of thrombospondin-1 and -2.
Lawler, Jack, and Michael Detmar. 2004. “Tumor Progression: The Effects of Thrombospondin-1 and -2.”. The International Journal of Biochemistry & Cell Biology 36 (6): 1038-45.
Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis.
Cursiefen, Claus, Sharmila Masli, Tat Fong Ng, Reza Dana, Paul Bornstein, Jack Lawler, and Wayne Streilein. 2004. “Roles of Thrombospondin-1 and -2 in Regulating Corneal and Iris Angiogenesis.”. Investigative Ophthalmology & Visual Science 45 (4): 1117-24.
Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression.
Hamano, Yuki, Hikaru Sugimoto, Mary A Soubasakos, Mark Kieran, Bjorn R Olsen, Jack Lawler, Akulapalli Sudhakar, and Raghu Kalluri. 2004. “Thrombospondin-1 Associated With Tumor Microenvironment Contributes to Low-Dose Cyclophosphamide-Mediated Endothelial Cell Apoptosis and Tumor Growth Suppression.”. Cancer Research 64 (5): 1570-4.
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy.
Bocci, Guido, Giulio Francia, Shan Man, Jack Lawler, and Robert S Kerbel. 2003. “Thrombospondin 1, a Mediator of the Antiangiogenic Effects of Low-Dose Metronomic Chemotherapy.”. Proceedings of the National Academy of Sciences of the United States of America 100 (22): 12917-22.
Thrombospondin 1–a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model.
Gutierrez, Linda S, Mark Suckow, Jack Lawler, Victoria A Ploplis, and Francis J Castellino. 2003. “Thrombospondin 1–a Regulator of Adenoma Growth and Carcinoma Progression in the APC(Min/+) Mouse Model.”. Carcinogenesis 24 (2): 199-207.
Activation of platelet-transforming growth factor beta-1 in the absence of thrombospondin-1.
Abdelouahed, M, A Ludlow, G Brunner, and J Lawler. 2000. “Activation of Platelet-Transforming Growth Factor Beta-1 in the Absence of Thrombospondin-1.”. The Journal of Biological Chemistry 275 (24): 17933-6.
Plasmodium falciparum-infected erythrocyte adhesion to the type 3 repeat domain of thrombospondin-1 is mediated by a modified band 3 protein.
Eda, S, J Lawler, and I W Sherman. 1999. “Plasmodium Falciparum-Infected Erythrocyte Adhesion to the Type 3 Repeat Domain of Thrombospondin-1 Is Mediated by a Modified Band 3 Protein.”. Molecular and Biochemical Parasitology 100 (2): 195-205.